The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, ...

An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

The use of RBL, a fecal microbiota-based live biotherapeutic, was safe and efficacious for recurrent CDI prevention in a large cohort of adults with common comorbidities.

Candidate CDI vaccine PF-06425090 was not effective for primary infection prevention but it was efficacious against CDI-related medical attention and antibiotic intervention.

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

Study finds underutilization of fidaxomicin, a recommended treatment for C. diff infection, despite increased use in hospitals.

The Hospital and Healthsystem Association of Pennsylvania on Tuesday recognized the Pennsylvania hospitals that have achieved exemplary results preventing infections — and St. Luke’s had more ...

Rockville, Maryland Saturday, October 5, 2024, 18:00 Hrs [IST] ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

Lankenau Medical Center and Riddle Hospital, both part of Main Line Health, have received statewide recognition for their outstanding performance in patient safety. The Hospital and ...

Acurx Pharmaceuticals (ACXP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

We recently compiled a list of the 7 Best High Short Interest Stocks To Invest In. In this article, we are going to take a ...